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Abstract
Serum des-Q-carboxy prothrombin (DCP) is a useful marker for the diagnosis of hepatocellular carcinoma (HCC), but the
exact mechanism of its synthesis and its structural properties in liver diseases are unknown. DCP is measured by the
monoclonal antibody MU-3. The purpose of this study was to examine the epitope of MU-3 and to characterize the
differences in DCP between HCC and benign liver diseases. The epitope of MU-3 was examined by ELISA using
prothrombin Gla domain polypeptides and was determined to be amino acid residues 17^27 of the prothrombin Gla domain,
which has four Q-carboxyglutamic acid residues (Gla) at positions 19, 20, 25 and 26. Peptides having a glutamic acid residue
(Glu) at these positions reacted strongly to MU-3 but lost reactivity when Glu 19 or 20 was changed to Gla. In the order of
Q-carboxylation, MU-3 reacted strongly to DCP containing 0^1 Gla, weakly to 2^4 Gla and not at all to DCP containing
more than five Gla. After adsorbing normal prothrombin with barium carbonate, DCP reaction to MU-3 was measured by
determining the amount of DCP that was adsorbed by MU-3-coated beads. The proportion of DCP reacting to MU-3 in
HCC was 41.0^76.8%, whereas in patients with benign liver diseases, only 0^42.1% reacted to MU-3. These results indicate
that DCP variants preferentially synthesized in HCC have less than four Gla, which are restricted to positions 16, 25, 26 and
29, whereas DCP variants in benign liver diseases have more than five Gla. ß 2002 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Prothrombin, a blood coagulation protein synthe-
sized in the liver, is converted to an active form after
the 10 Glu residues in the Gla domain at positions 6,
7, 14, 16, 19, 20, 25, 26, 29 and 32 are Q-carboxylated
to Gla by vitamin-K dependent Q-glutamyl carboxy-
lase. In patients with liver diseases, including
hepatocellular carcinoma (HCC) and liver cirrhosis,
prothrombin synthesis is reduced [1], and its Q-car-
boxylation is impaired so that des-Q-carboxy pro-
thrombin (DCP) or protein induced by the absence
of vitamin K (PIVKA-II) is formed instead [2]. Blan-
chard et al. [3] puri¢ed DCP and raised a polyclonal
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antibody in rabbits. By radioimmunoassay using this
antibody, they found that the serum DCP concentra-
tion was signi¢cantly high in patients with HCC [4].
Since then, the usefulness of DCP as a marker pro-
tein for the diagnosis of HCC has been con¢rmed by
clinical data [4,5]. It is noteworthy that the elevation
of DCP does not correlate with that of K-fetoprotein
[5], and a high positive rate is reported in HCC pa-
tients with hepatitis C virus infection [6], which is
now a worldwide problem [7,8]. In addition, a detect-
able amount of DCP is also found in benign liver
diseases such as cirrhosis, although the concentration
is signi¢cantly lower than that of HCC [2,9].
However, it has not yet been determined whether
the di¡erence between DCP in HCC and DCP in
benign liver diseases is due to its quantity or its qual-
ity. Clarifying the des-Q-carboxylation of DCP in
HCC might provide a key to understanding the
mechanism of the characteristic features of DCP in
HCC. Liebman et al. [10] puri¢ed DCP from ascites
£uid of patients with HCC by immunoa⁄nity chro-
matography and analyzed its Gla content and het-
erogeneity by tube gel electrophoresis in the presence
of calcium. They reported that the average number
of Gla of DCP was ¢ve per molecule. Instead of
using a polyclonal antibody, Owens et al. [11], Belle
et al. [12] and Grosley et al. [13] made monoclonal
antibodies and established assay systems with higher
sensitivity. Even though their assay systems were sat-
isfactory for the sero-diagnosis of HCC and their
monoclonal antibodies reacted with prothrombin in
the presence of EDTA, the epitopes have not been
determined yet.
MU-3 antibody is a monoclonal antibody raised
against DCP by Motohara et al. [14,15]. Clinical
studies have demonstrated that immunoassay using
MU-3 antibody [16] has a high sensitivity to and
speci¢city for DCP in HCC and that DCP measure-
ment is useful for the early detection of HCC [5,17^
23]. Sugo et al. [24] reported that the reactivity of
MU-3 antibody increased when the number of Gla
was less than ¢ve per molecule. Recently, it was re-
ported that the Q-carboxylation of 10 Gla did not
occur randomly but according to the ¢xed order
[25^27] of 26, 25, 16, 29, 20, 19, 14, 32, 7 and 6
[28]. If the epitope and the part of DCP reacting to
MU-3 antibody were clear, it would be possible to
determine the Gla content of DCP by comparing the
order of the Q-carboxylation. The purpose of this
study was to examine the di¡erence between DCP
in HCC and benign liver diseases using MU-3 anti-
body reactivity.
2. Materials and methods
2.1. Preparation of proteins
Human prothrombin, factor IX and factor X were
puri¢ed from citrated human plasma by barium cit-
rate precipitation, ammonium sulfate elution, DEAE
Sepharose FF chromatography, heparin Sepharose
CL-6B chromatography, Blue Sepharose CL-6B
chromatography and Sephacryl S-200 HR chroma-
tography [29]. Rat prothrombin was prepared by a
slight modi¢cation of the puri¢cation method for rat
factor X reported by Enjyoji et al. [30]. All puri¢ed
proteins migrated as a single band on SDS^polyac-
rylamide gel electrophoresis by the method of
Laemmli et al. [31]. After adding K-chymotrypsin
(Sigma-Aldrich, St. Louis, MO, USA) at 3000:1
(w/w) to prothrombin fragment 1 prepared from pu-
ri¢ed prothrombin [32] by incubating at 30‡C for
30 min, the Gla domain was puri¢ed by Q Sepharose
FF chromatography [33]. The Gla domain migrated
as a single band on polyacrylamide gel electrophore-
sis by the method of Burr et al. [34], and the amino
acid composition was con¢rmed by the method of
Spackman et al. [35]. MU-3 antibody IgG1 was pu-
ri¢ed using a protein A Sepharose CL-4B column
[36] from the ascitic £uid of a mouse injected intra-
peritoneally with hybridoma cells secreting MU-3
antibody.
2.2. Decarboxylation of Gla residues and
determination of Gla content
Gla of human prothrombin, the Gla domain, fac-
tor IX, factor X and rat prothrombin were decar-
boxylated as described by Bajaj et al. [37]. After add-
ing diisopropyl £uorophosphate and EDTA at a
concentration of 5 mM and 10 mM respectively, pro-
teins were dialyzed against 0.1 M ammonium bicar-
bonate, pH 8.0, prepared from distilled water treated
with Chelex 100 (Bio-Rad, Hercules, CA, USA).
After dialysis, proteins were lyophilized and heated
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at 110‡C for 8 h under a vacuum of less than 50
pascal. When dissolved in phosphate bu¡ered saline
(PBS), all decarboxylated proteins migrated as a sin-
gle band on SDS^polyacrylamide gel electrophoresis.
Gla content was examined by the method of Kuwada
et al. [38], and protein concentrations were deter-
mined with micro BCA protein assay reagent (Pierce,
Rockford, IL, USA).
2.3. Gla domain polypeptide
Peptides used for epitope determination were pur-
chased from the Peptide Institute (Osaka, Japan).
The amino acid sequence of all peptides, including
synthetic peptides in which Gla residues were substi-
tuted for Glu residues, were based on the sequence
reported by Degen et al. [39]. The purity of all pep-
tides was con¢rmed to be more than 99% by HPLC,
and the amino acid compositions were determined by
the method of Spackman et al. [35].
2.4. Serum from patients and normal volunteers
Serum samples were taken from 24 informed and
consenting patients with various liver diseases: seven
with HCC, seven with liver cirrhosis (LC), ¢ve with
alcoholic liver disease (ALD) and ¢ve with chronic
hepatitis (CH), and two normal volunteers.
2.5. Direct binding ELISA
Reactivity of MU-3 antibody to decarboxylated
proteins and to synthetic peptides was measured by
ELISA using 96-well microtiter plates (Nalge Nunc
International, Rochester, NY, USA). Decarboxy-
lated proteins or synthetic peptides diluted in TBS
(50 mM Tris^HCl, 0.1 M NaCl, pH 8.0) were coated
on the wells of microtiter plates by incubating for 5 h
at room temperature. After three washes with TBS,
wells were blocked with 1% bovine serum albumin^
TBS (BSA^TBS) for 1 h. After a washing with TBS,
a solution of MU-3 antibody diluted at various con-
centrations with 0.1% Tween 20^BSA^TBS was
added to each well. After incubation at room temper-
ature for 2 h and a wash, wells reacted with MU-3
antibody were further incubated with a solution of
horseradish peroxidase-labeled rabbit anti-mouse
IgG antibody (ICN Pharmaceuticals, Irvine, CA,
USA) at room temperature for 1 h. After further
washes, the wells were incubated with 1 mg/ml
Y-phenylenediamine and 2 mM H2O2 dissolved in
0.1 M citrate bu¡er, pH 5.5. The reaction was
stopped by adding 2 N sulfuric acid, and the absor-
bance at 492 nm was read using a microplate photo-
meter.
2.6. Sandwich ELISA
Sandwich ELISA was performed by the method
used for direct binding ELISA except that, in place
of decarboxylated proteins, MU-3 antibody was
coated on the wells, and in place of horseradish per-
oxidase-labeled rabbit anti-mouse IgG antibody,
horseradish peroxidase-labeled Fab of a⁄nity puri-
¢ed rabbit anti-prothrombin antibody was used. De-
carboxylated prothrombin diluted with 3% BSA^
TBS was used as a reference standard protein.
2.7. Total DCP assay and DCP adsorption using
MU-3 antibody
Because it has been reported that the concentra-
tion of DCP in serum of patients with liver diseases,
including HCC, was the same as that in plasma [13],
we used serum as samples. Sera from patients and
normal volunteers were diluted 10-fold with 0.2%
BSA^TBS, barium carbonate was added at 10%
(w/v), and the mixture was stirred thoroughly. The
precipitate was removed by centrifugation and the
supernatant was obtained. This barium-adsorbed
supernatant was diluted with 3% BSA^TBS, and
the prothrombin antigen concentration (referred as
total DCP) was measured by sandwich ELISA, using
wells coated with anti-prothrombin antibody. A
standard curve was prepared using known concen-
trations of puri¢ed prothrombin diluted with 3%
BSA^TBS.
The amount of DCP reacting to MU-3 antibody
was measured as follows. First, a solid phase coated
with MU-3 antibody was obtained using Dynabeads
M450 (Dynal, Oslo, Norway) at a concentration of
1 mg of MU-3 antibody IgG per 4U108 beads.
Beads coated with MU-3 antibody were added at
2U107 per 50 Wl of supernatant obtained by barium
precipitate, and after incubating for 2 h at room
temperature, beads were removed using a magnetic
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separator. The quantity of MU-3 antibody added to
the sample was enough to adsorb all the DCP be-
cause 50 Wg (312 pmol) were added, while 50 Wl of
the supernatant contained only 0.5 Wg (7 pmol) of
DCP, even when all the prothrombin in a sample was
converted to DCP. The DCP concentration of the
solution after removal of the beads was measured
by the same method used for measuring the total
DCP concentration, and the percentage of DCP re-
acting to MU-3 antibody was calculated. The results
are represented as mean values þ S.D. Mann^Whit-
ney’s U-test was used for statistical analysis, and the
signi¢cance level was de¢ned as P6 0.01.
3. Results
3.1. The e¡ect of calcium ions and EDTA on
MU-3 antibody reaction
Because the Gla domain of prothrombin under-
goes a metal-induced conformational change [11],
MU-3 antibody reactivities to DCP and to pro-
thrombin were examined in the presence or absence
of calcium ions and EDTA using the sandwich ELI-
SA with wells coated with MU-3 antibody. As shown
in Fig. 1, MU-3 antibody reacted to decarboxylated
prothrombin and serum of patients with HCC in the
presence or absence of 10 mM calcium ions and
20 mM EDTA. In contrast, MU-3 antibody failed
to react to puri¢ed prothrombin in the presence or
absence of 10 mM calcium ions and 20 mM EDTA.
These results indicate that the MU-3 antibody binds
to DCP but does not bind to prothrombin regardless
of the presence or absence of calcium ions and
EDTA, suggesting that MU-3 antibody does not rec-
ognize the conformational change of the Gla do-
main. It also suggests that MU-3 antibody is com-
pletely di¡erent from JO1.1 and C4B6 antibodies
[11,12], the recognition of which is conformation-de-
pendent, because they react with DCP and pro-
thrombin in the presence of EDTA.
Fig. 2. Amino acid sequences of the Gla domain and peptides
used for epitope determination. Amino acids are represented by
the single letter code. Gla residues are denoted by Q. Kd is cal-
culated using Figs. 3, 4 and 7.
Fig. 1. E¡ect of calcium ions and EDTA on MU-3 antibody re-
action. Decarboxylated prothrombin in the presence of calcium
ions (a) or EDTA (O), or in the absence of both (E), pro-
thrombin in the presence of calcium ions (b) or EDTA (R), or
in the absence of both (F), and serum of a patient with HCC
in the presence of calcium ions (8) or EDTA (S), or in the
absence of both (U), were tested using a sandwich ELISA with
MU-3 antibody-coated wells. The protein concentration of
DCP in serum of a patient with HCC was determined from the
total DCP adsorbed by MU-3 antibody.
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3.2. The reactivity of MU-3 antibody to
decarboxylated prothrombin, decarboxylated Gla
domain, peptide-1, peptide-2 and peptide-3
Direct binding ELISA with wells coated with de-
carboxylated prothrombin, decarboxylated Gla do-
main and three peptides was used to analyze the epi-
tope of MU-3 antibody. The Gla contents of
decarboxylated human prothrombin and the decar-
boxylated Gla domain were 0.7 Gla per molecule and
1.0 Gla per molecule, respectively. The amino acid
sequences of the decarboxylated Gla domain (resi-
dues 1^41), peptide-1 (residues 1^16), peptide-2 (res-
idues 11^30) and peptide-3 (residues 23^41) are pre-
sented in Fig. 2, in addition to those of peptide-4 to
peptide-22, which were used for further analysis. The
reactivity of MU-3 antibody is shown in Fig. 3, and
the dissociation constant (Kd) for MU-3 antibody
calculated from the results shown in Fig. 3 is pre-
sented in Table 1. The results of Kd of all peptides
obtained from further analysis are summarized in
Fig. 2.
MU-3 antibody showed almost the same reactivity
to decarboxylated prothrombin, the decarboxylated
Gla domain and peptide-2, but no reactivity to pep-
tide-1 and peptide-3. These results indicate that the
epitope of MU-3 antibody contains only the Gla
domain, and that other domains, including fragment
1 and fragment 2, do not participate in the reaction
to MU-3 antibody. Furthermore, the presence of
the epitope of MU-3 antibody within peptide-2 and
the similarity of the Kd of peptide-2 and the decar-
boxylated Gla domain suggest that the residues at
positions 11^30 of decarboxylated prothrombin
have the same conformational structure as that of
peptide-2.
3.3. Determination of the MU-3 antibody epitope
To specify the epitope in peptide-2 in more detail,
examination with smaller peptides was necessary, but
peptides smaller than peptide-2 were di⁄cult to bind
directly to the wells. Therefore, the MU-3 antibody
epitope was examined with competing peptides
against decarboxylated prothrombin by sandwich
ELISA using wells coated with MU-3 antibody. De-
carboxylated prothrombin activity with MU-3 anti-
body after the competition with each peptide was
expressed as relative activity. Peptide-5 (residues
13^27) and peptide-6 (residues 17^27) inhibited the
reaction to MU-3 antibody and showed the same
reactivity as peptide-2, but peptide-7 (residues 17^
24) reacted only weakly to MU-3 antibody (Fig. 4).
From these results, it becomes clear that the epitope
of MU-3 antibody consists of, at least, residues at
positions 17^27. Therefore, it is evident that the ami-
no acid sequence of positions 17^27 in the Gla do-
main has a peculiar structure because it binds to
MU-3 antibody, although the whole Gla domain in
DCP has a disordered structure. One of the peculiar-
ities of residues 17^27 is the structure of the s^s
bond; after the dissociation of the s^s bond, MU-3
antibody did not react to residues 17^27 (data not
shown).
Table 1
Dissociation constant for MU-3 antibody and decarboxylated
human prothrombin, decarboxylated Gla domain and peptide-2
Decarboxylated proteins Kad (nM)
Decarboxylated prothrombin 0.88
Decarboxylated Gla domain (residues 1^41) 1.5
Peptide-2 (residues 11^30) 1.2
aThe dissociation constant (Kd) was determined by ¢tting Fig. 3
data to reciprocals of OD 492 nm against reciprocals of MU-3
antibody concentration.
Fig. 3. Reactivity of MU-3 antibody to decarboxylated pro-
thrombin, decarboxylated Gla domain, peptide-1, peptide-2 and
peptide-3. MU-3 antibody was incubated in wells coated with
decarboxylated prothrombin (a), decarboxylated Gla domain
(U), peptide-2 (11^30: GNLERECVEETCSYEEAFEA, O),
peptide-1 (1^16: ANTFLEEVRKGNLERE, E) or peptide-3
(23^41: SYEEAFEALESSTATDVFW, b), and the MU-3 anti-
body that reacted was measured by direct binding ELISA.
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3.4. MU-3 antibody reactivity to several coagulation
factors
Human factor IX, human factor X and rat pro-
thrombin were decarboxylated and measured by di-
rect binding ELISA to clarify which amino acid res-
idues were responsible for the epitope formation. As
is seen in Fig. 5, the reactivity of decarboxylated
human factor X to MU-3 antibody was almost the
same as that of decarboxylated human prothrombin,
and the Kd calculated was 1.45 nM, which was al-
most equal to the Kd of decarboxylated human pro-
thrombin, suggesting that the amino acid sequence at
positions 17^27 in decarboxylated human factor X
has the same conformational structure as DCP.
However, MU-3 antibody reacted very weakly to
decarboxylated rat prothrombin and did not react
to decarboxylated human factor IX. This weak reac-
tivity could be explained by the absence of threonine
at position 21 of decarboxylated factor IX and rat
prothrombin as shown in Fig. 6 [40^42]. Taken to-
gether, threonine at position 21 apparently plays an
important role in the epitope conformation.
3.5. Position and number of Gla and Glu in the
epitope
Between positions 17 and 27 in the Gla domain,
there are four Gla residues (positions 19, 20, 25 and
26), and so there are 16 possible combinations to
convert each Gla to Glu. Therefore, we produced
16 kinds of peptides (peptides 6, 8^22 in Fig. 2)
and examined the reactivity of each peptide to
MU-3 antibody by sandwich ELISA. As shown in
Fig. 7, peptide-6 and peptide-11, both of which con-
tain Glu at positions 19, 20 and 25, inhibited the
reaction strongly, but peptide-10 and peptide-12,
both of which contain Glu at positions 19 and 20
and Gla at position 25, inhibited it weakly. MU-3
Fig. 6. Amino acid sequences of the Gla domain of human pro-
thrombin, factor X, factor IX and rat prothrombin. Amino
acids at positions 17^27 that are di¡erent from those in human
prothrombin are grayed out. Gla residues are denoted by Q. Kd
is calculated from the results of Fig. 5.
Fig. 5. Reactivity of MU-3 antibody to decarboxylated human
prothrombin, decarboxylated human factor X, decarboxylated
human factor IX and decarboxylated rat prothrombin. MU-3
antibody was incubated in wells coated with decarboxylated hu-
man prothrombin (a), decarboxylated human factor X (O), de-
carboxylated human factor IX (E) or decarboxylated rat pro-
thrombin (U), and the amount of MU-3 antibody that reacted
was measured by direct binding ELISA.
Fig. 4. Inhibition of MU-3 antibody reactivity to decarboxy-
lated prothrombin by peptides. Decarboxylated prothrombin
was mixed with peptide-2 (11^30: GNLERECVEETCSYEEA-
FEA, a), peptide-4 (1^17: ANTFLEEVRKGNLEREC, E),
peptide-5 (13^27: LERECVEETCSYEEA, O), peptide-6 (17^
27: CVEETCSYEEA, U) or peptide-7 (17^24: CVEETCSY,
b), and inhibition of the reaction of decarboxylated prothrom-
bin to antibody by each peptide was measured by sandwich
ELISA.
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antibody did not react to peptide-8, peptide-9 and
peptide-13. Four other peptides with two Gla, four
peptides with three Gla and a peptide with four Gla
also did not react (data not shown). It suggests that
the Glu at positions 19 and 20 are essential for MU-3
antibody binding and that the further addition of
Glu at position 25 augments the binding. Therefore,
by comparison with the order of Q-carboxylation [28]
illustrated in Table 2, MU-3 antibody mainly reacts
to DCP with less than four Gla, which are restricted
to positions 16, 25, 26 and 29, and contains other
Gla (at positions 6, 7, 14, 19, 20, 32) without Q-car-
boxylation.
3.6. Percentage of DCP reacting to MU-3 antibody in
liver diseases
Table 3 shows the concentrations of prothrombin,
total DCP and DCP measured by ELISA, and the
concentration and percentage of DCP after MU-3
antibody adsorption. The total DCP concentration
in HCC ranged from 39.5 ng/ml to 413.6 ng/ml
and in benign liver diseases from 35.1 ng/ml to
368.6 ng/ml; therefore, there was no di¡erence be-
tween HCC and benign liver diseases. On the other
hand, the percentage of DCP reacting to MU-3 anti-
body in patients with HCC was 41.0^76.8%, whereas
it was 0^42.1% in patients with benign liver diseases.
Because MU-3 antibody mainly reacts to DCP with
less than four Gla, DCP variants preferentially syn-
thesized in HCC have less than four Gla, whereas
DCP variants abundant in benign liver diseases
have more than four Gla.
4. Discussion
In the present study, we determined that the epi-
tope of MU-3 antibody was located at amino acid
Table 2
Relationship between the total number of Gla residues and MU-3 antibody reactivity
Total number of Gla
residues
Position of Gla in DCPa Reactivity to
MU-3 antibody
Gla 6 Gla 7 Gla 14 Gla 16 Gla 19 Gla 20 Gla 25 Gla 26 Gla 29 Gla 32
10 Q Q Q Q Q Q Q Q Q Q 3
9 E Q Q Q Q Q Q Q Q Q 3
8 E E Q Q Q Q Q Q Q Q 3
7 E E Q Q Q Q Q Q Q E 3
6 E E E Q Q Q Q Q Q E 3
5 E E E Q E Q Q Q Q E 3
4 E E E Q E E Q Q Q E +
3 E E E Q E E Q Q E E +
2 E E E E E E Q Q E E +
1 E E E E E E E Q E E +++
0 E E E E E E E E E E +++
aQ-Carboxylation order is illustrated as reported by Uehara et al. Gla residues are denoted by Q. Glu residues are denoted by E.
Fig. 7. Inhibition of MU-3 antibody reactivity to decarboxy-
lated prothrombin by various peptides with residues at posi-
tions 17^27 having di¡erent Gla and Glu positions. Decarboxy-
lated prothrombin was mixed with peptide-6 (17^27:
CVEETCSYEEA, U), peptide-8 (17^27: CVQETCSYEEA, a),
peptide-9 (17^27: CVEQTCSYEEA, O), peptide-10 (17^27:
CVEETCSYQEA, b), peptide-11 (17^27: CVEETCSYEQA, R),
peptide-12 (17^27: CVEETCSYQQA, E), or peptide-13 (17^27:
CVQQTCSYEEA, F), and inhibition of the reaction of decar-
boxylated prothrombin to antibody by each peptide was mea-
sured by sandwich ELISA.
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Table 3
Percentage of DCP reacting to MU-3 antibody in various liver diseases
Patient
No.
Diagnosisa Prothrombin
concentration
(Wg/ml)
DCP by ELISA
MU-3 antibody
(mAU/ml)
After prothrombin adsorption using barium carbonate
Total DCP
(ng/ml) (A)
After adsorbed by
MU-3 antibody
beads (ng/ml) (B)
DCP reacted to
MU-3 antibody
(ng/ml) (A3B = C)
Percentage (%)
(100UC/A)
Average (%)
(S.D.)
1 HCC 98.9 281.4 375.1 221.1 154.0 41.0
2 HCC 61.3 46.8 67.5 27.6 39.9 59.1
3 HCC 99.3 60.5 63.7 29.6 34.1 53.5
4 HCC 40.4 12.4 39.5 17.3 22.2 56.1 57.5
5 HCC 106.6 1035.5 413.6 189.5 224.1 54.2 (10.8)
6 HCC 92.0 99.4 238.9 91.1 147.7 61.9
7 HCC 93.8 181.3 133.6 31.0 102.6 76.8
8 LC 72.3 82.8 35.1 21.5 13.6 38.7
9 LC 33.4 93.1 153.2 110.3 42.9 28.0
10 LC 77.1 108.9 36.2 21.0 15.3 42.1 23.7*
11 LC 98.2 12.4 49.1 40.2 8.9 18.2 (14.3)
12 LC 94.0 22.7 295.5 244.2 51.3 17.4
13 LC 102.1 15.0 353.2 363.9 310.8 0
14 LC 94.0 12.4 368.6 289.0 79.6 21.6
15 ALD 99.1 52.3 87.9 59.3 28.6 32.5
16 ALD 104.9 210.1 178.9 145.1 33.8 18.9
17 ALD 70.0 30.4 54.4 38.3 16.1 29.6 30.4**
18 ALD 96.6 106.4 81.6 47.6 34.0 41.7 (8.2)
19 ALD 101.8 33.9 101.7 71.9 29.8 29.3
20 CH 94.4 16.1 96.8 80.7 16.1 16.6
21 CH 105.8 5.7 137.4 85.9 51.5 37.5 25.3***
22 CH 82.9 17.2 331.4 238.2 93.1 28.1 (13.7)
23 CH 99.7 17.7 46.8 28.9 17.8 38.1
24 CH 105.0 17.7 84.3 78.9 5.4 6.4
25 Nor 99.8 5.5 19.3 17.0 2.3 12.1
26 Nor 105.3 15.0 26.9 19.0 7.9 29.5
Compared with HCC: *P6 0.01; **P6 0.01; ***P6 0.01.
aHCC, hepatocellular carcinoma; LC, liver cirrhosis ; ALD, alcoholic liver disease; CH, chronic hepatitis ; Nor, normal volunteer.
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residues 17^27 in the Gla domain. By determining
the positions of Gla in DCP and comparing them
with the order of Q-carboxylation, we found that
MU-3 antibody reacted to DCP with less than four
Gla. Measuring DCP in patients with liver diseases
by adsorbing prothrombin with barium carbonate
and determining the content of DCP reacting to
MU-3 antibody clari¢ed that DCP variants occur-
ring in HCC contain less than four Gla in a higher
proportion than that found in benign liver disease.
It is well known that the prothrombin Gla domain
takes a very compact and stable conformational
structure in the presence of calcium ions and requires
calcium ions for its physiological function. However,
in the absence of calcium ions, the Gla domain has
an irregular form [43]. Because DCP lacks blood
coagulation activity even if calcium ions are present,
it is unable to take the conformation necessary to
bind to the phospholipid surface where the pro-
thrombin activation occurs [44]. Although the whole
Gla domain in DCP has a disordered structure, our
result assumes a characteristic structure in amino
acid residues 17^27 of the Gla domain of DCP be-
cause it binds to MU-3 antibody. The existence of a
characteristic structure in DCP is also supported by
the reactivity of MU-3 antibody to decarboxylated
factor X.
Sixteen combinations of changes of the four Gla to
Glu at positions 17^27 of the Gla domain are possi-
ble. Among the combinations, our immunoassay
analysis using di¡erent peptides showed that
Glu19Glu20Glu25Glu26 and Glu19Glu20Glu25Gla26
strongly bind to MU-3 antibody, whereas peptides
Glu19Glu20Gla25Glu26 and Glu19Glu20Gla25Gla26
with Gla residues at position 25 bound weakly to
MU-3 antibody, and no binding was observed
when one or both of the Glu at position 19 or 20
were Q-carboxylated. Comparing the epitope with the
order of Q-carboxylation, it was possible to determine
the Gla content of DCP variants reacting to MU-3
antibody. Three di¡erent Q-carboxylation orders have
been reported [25,27,28]. Borowski et al. [25] re-
ported that the Q-carboxylation in patients with a
hereditary defect in vitamin K-dependent carboxyla-
tion occurred in the order Gla6, Gla14, Gla19, Gla20,
which were initially Q-carboxylated, Gla29 next, and
then Gla16 and Gla7. Ratcli¡e et al. [27] examined
the in£uence of each Gla on blood coagulation ac-
tivity by changing Gla into aspartic acid and found
that the importance of Gla to the blood coagulation
activity was in the order of Gla16, Gla26, Gla29,
Gla19, Gla7, Gla25, Gla20, Gla14, Gla32 and Gla6.
Therefore, it is very likely that DCP receives Q-car-
boxylation in this order. Our results indicate that the
peptide covering positions 17^27 decreased its bind-
ing activity to MU-3 antibody when Glu19 or Glu20
are Q-carboxylated. From this result, we can presume
that the DCP bound to MU-3 antibody has a max-
imum of two Gla according to the order reported by
Borowski et al. [25], three Gla according to Ratcli¡e
et al. [27], and four Gla according to Uehara et al.
[28].
An important issue to resolve is how many Gla are
present in DCP of HCC. Liebman et al. [10] reported
that hepatoma-associated DCP contained an average
of ¢ve Gla per molecule. In contrast to their results,
our data show that DCP with less than four Gla
residues per molecule is abundant in hepatoma-asso-
ciated DCP. The reason for this discrepancy is not
clear, but several possibilities might explain it. One is
the method used to purify DCP: Liebman et al. [10]
puri¢ed DCP by ion exchange chromatography and
immunoa⁄nity chromatography, whereas we used
barium salt and MU-3 adsorption. Grosley et al.
[13] reported that several barium salts had di¡erent
adsorption properties toward prothrombin and
DCP; therefore, barium carbonate, which adsorbs
only prothrombin and not DCP, was selected in
our study. The second possibility is the di¡erence
of materials used for puri¢cation: Liebman et al.
puri¢ed from patient ascites £uid whereas we used
patient serum. The results of normal volunteers
showed that some prothrombin might remain unad-
sorbed and a¡ect the results. However, this possibil-
ity is unlikely because MU-3 antibody did not bind
to prothrombin, and unadsorbed prothrombin did
not a¡ect the result that serum of HCC patients con-
tained a much higher concentration of DCP ad-
sorbed by MU-3 antibody than that of benign liver
disease patients. From these results, we may con-
clude that the DCP variants preferentially synthe-
sized in HCC have less than four Gla, whereas in
benign liver diseases, DCP with more than four
Gla are abundant. The reason why DCP with less
than four Gla is abundant in HCC could be ex-
plained by the mechanism of DCP synthesis.
BBADIS 62090 26-4-02
T. Naraki et al. / Biochimica et Biophysica Acta 1586 (2002) 287^298 295
For the mechanism of DCP synthesis in HCC, the
following possibilities were proposed: a prothrombin
gene mutation in the pre-propeptide region [45],
overproduction of prothrombin [46,47], vitamin K
de¢ciency or defect of the vitamin K cycle in liver
cells [48,49], participation of cytokines [50], and an
abnormality of Q-glutamyl carboxylase [51]. How-
ever, it is noteworthy that, in addition to DCP,
des-Q-carboxyl protein C [52] and the des-Q-carboxyl
form of other coagulation factors [53] are also syn-
thesized in HCC patients. From our results, there is a
high possibility of low Gla content in des-Q-carboxyl
protein C and other coagulation factors synthesized
in HCC. Therefore, the mechanism of DCP synthesis
in HCC should be reconsidered from the viewpoint
that the Q-carboxylation of all vitamin K-dependent
coagulation factors in the liver cells of benign liver
diseases might be slightly defective, whereas in HCC
patients, the Q-carboxylation might be severely af-
fected. The causes for DCP synthesis in HCC most
suitable for explaining our results are vitamin K de-
¢ciency in HCC liver cells, a defective vitamin K
cycle and an abnormality of Q-glutamyl carboxylase
in HCC liver cells. Further studies are needed to
clarify this issue.
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